Lexaria Bioscience Corp Stock Today

Stocks . USA . 
Stock . Lexaria Bioscience Corp
LEXXW Stock  USD 0.75  0.12  19.05%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 20

 
High
 
Low
Low
Lexaria Bioscience is selling for under 0.75 as of the 27th of November 2024; that is 19.05% increase since the beginning of the trading day. The stock's lowest day price was 0.68. Lexaria Bioscience has about a 20 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Lexaria Bioscience Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of May 2023 and ending today, the 27th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of January 2021
Category
Healthcare
Classification
Health Care
Lexaria Bioscience Corp. operates in the drug delivery platform business. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. Lexaria Bioscience is traded on NASDAQ Exchange in the United States. More on Lexaria Bioscience Corp

Moving together with Lexaria Stock

  0.66ME 23Andme HoldingPairCorr
  0.8VALN Valneva SE ADRPairCorr
  0.67JNJ Johnson Johnson Sell-off TrendPairCorr

Moving against Lexaria Stock

  0.65KZR Kezar Life SciencesPairCorr
  0.48MLYS Mineralys Therapeutics,PairCorr
  0.37MDGL Madrigal PharmaceuticalsPairCorr

Lexaria Stock Highlights

President DirectorJohn MSc
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Materials, Materials (View all Sectors)
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.320.3071
Sufficiently Up
Slightly volatile
Total Current Liabilities472.9 K241 K
Way Up
Slightly volatile
Non Current Liabilities Total216.6 K122.6 K
Way Up
Slightly volatile
Total Assets4.1 M3.5 M
Fairly Up
Slightly volatile
Total Current Assets2.2 M2.5 M
Fairly Down
Slightly volatile
Lexaria Bioscience can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lexaria Bioscience's financial leverage. It provides some insight into what part of Lexaria Bioscience's total assets is financed by creditors.
Liquidity
Lexaria Bioscience Corp has accumulated 163.97 K in total debt with debt to equity ratio (D/E) of 0.06, which may suggest the company is not taking enough advantage from borrowing. Lexaria Bioscience Corp has a current ratio of 8.35, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Note, when we think about Lexaria Bioscience's use of debt, we should always consider it together with its cash and equity.

Begin Period Cash Flow

7.02 Million
Lexaria Bioscience Corp (LEXXW) is traded on NASDAQ Exchange in USA. It is located in 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7 and employs 5 people. Lexaria Bioscience is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 33.79 M. Lexaria Bioscience Corp classifies itself under Biotechnology sector and is part of Health Care industry. Lexaria Bioscience Corp has accumulated about 1.31 M in cash with (5.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44.
Check Lexaria Bioscience Probability Of Bankruptcy

Lexaria Bioscience Historical Income Statement

At this time, Lexaria Bioscience's Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to climb to about 125.2 K in 2024, despite the fact that EBIT is likely to grow to (5.6 M). View More Fundamentals
Other Operating Expenses  Total Operating Expenses  Total Revenue  

Lexaria Stock Against Markets

 Competition   Compare Correlations

Lexaria Bioscience Corporate Management

Christopher BunkaChairman CEOProfile
Vanessa CarleHead LegalProfile
Philip AinslieAdvisor ConsultantProfile
Nelson CPAChief OfficerProfile
Richard ChristopherChief OfficerProfile
Michael CPAChief OfficerProfile

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY